Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:23 PM
Ignite Modification Date:
2025-12-24 @ 5:23 PM
NCT ID:
NCT01743950
Eligibility Criteria:
Inclusion Criteria:
* Histologically or molecularly confirmed Grade 3 or 4 glioma, IDH mutant or wildtype, as defined by the 2021 WHO guidelines
* Recurrent disease based on combination of clinical, imaging or histologic confirmation
* Must have previously received radiation and temozolomide to treat their glioma
* Bevacizumab naive patients must be \> 5 months post completion of initial radiation therapy
* Bevacizumab exposed patients must be \> 3 months post completion of initial radiation therapy
* Age must be \>18years, KPS must be greater than 60
* Hematology, chemistry and a urinalysis must meet protocol specified criteria
Exclusion Criteria:
* Pregnant or breastfeeding
* Uncontrolled hypertension (\>160/90mmHg)
* Prior malignancy unless treated \>1 year prior to study and have been without treatment and disease free for 1 yr
* active second malignancy unless non-melanoma skin cancer or cervical cancer in situ
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01743950
Study Brief:
Protocol Section:
NCT01743950